TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.

Department of Health and Human Services

Award: Department of Health and Human ServicesNAICS n/aSAM# 75N93020C00018

Posted 2026-07-19 · Response deadline 2026-08-31 · Set-aside: None

Recipient: REVAGENIX INC | $26944786.61

View official SAM.gov notice →

← All opportunities